Use of targeted oxidative therapeutic formulation in treatment of age-related macular degeneration
A pharmaceutical formulation and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (“DMSO”); a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to effectively treat patients affected with age-related macular degeneration (“ARMD”).
1 . A method for treating a patient with age-related macular degeneration (“ARMD”) comprising:
administering to the patient an effective amount of a pharmaceutical formulation comprising:
peroxidic species or reaction products resulting from oxidation of menthol or an alkene by an oxygen-containing oxidizing agent, wherein the alkene comprises terpineol, citronellol, nerol, linalool, phytol, geraniol, perillyl alcohol, menthol, geranylgeraniol or farnesol, and wherein the peroxidic species or reaction products resulting from oxidation of menthol or the alkene is from about 0.001% to about 30% by weight of the pharmaceutical formulation;
a penetrating solvent, wherein the penetrating solvent comprises dimethylsulfoxide, sterol, lecithin, propylene glycol, or methylsulfonylmethane, and wherein the penetrating solvent is from about 50% to about 99% by weight of the pharmaceutical formulation;
a dye containing a chelated divalent or trivalent metal, wherein the dye comprises porphyrin, rose bengal, chlorophyllin, hemin, corrins, texaphrin, methylene blue, hematoxylin, eosin, erythrosin, lactoflavin, anthracene dye, hypericin, methylcholanthrene, neutral red, phthalocyanine, fluorescein, eumelanin, or pheomelanin, and wherein the dye is from about 0.1% to about 30% by weight of the pharmaceutical formulation; and
an aromatic redox compound, wherein the redox compound comprises substituted or unsubstituted benzoquinone, naphthoquinone, or anthroquinone, and wherein the aromatic redox compound is from about 0.01% to about 20% by weight of the pharmaceutical formulation.
2 . The method of claim 1 , wherein the alkene is in a liquid form, in a solution, or in a dispersion.
3 . The method of claim 1 , wherein the alkene is contained in a fixed oil, an ester, a fatty acid, or an ether.
4 . The method of claim 1 , wherein the oxygen-containing oxidizing agent comprises singlet oxygen, oxygen in its triplet state, superoxide anion, periodate, hydroxyl radical, hydrogen peroxide, alkyl peroxide, carbamyl peroxide, benzoyl peroxide, or oxygen bound to a transition element.
5 . The method of claim 1 , wherein the oxygen-containing oxidizing agent comprises ozone.
6 . The method of claim 1 , wherein the penetrating solvent is a liquid, micelle membrane, liposome, emollient, or vapor.
7 . The method of claim 1 , wherein the penetrating solvent is dimethylsulfoxide (“DMSO”).
8 . The method of claim 1 , wherein the dye comprises porphyrin, rose bengal, or a mixture thereof.
9 . The method of claim 1 , wherein the metal comprises iron.
10 . The method of claim 1 , wherein the metal comprises copper, manganese, tin, magnesium, or strontium.
11 . The method of claim 1 , further comprising an electron donor.
12 . The method of claim 11 , wherein the electron donor comprises ascorbic acid or a pharmaceutical salt thereof.
13 . A method for treating a patient with age-related macular degeneration (“ARMD”) comprising:
administering to the patient an effective amount of a pharmaceutical formulation comprising:
peroxidic species or reaction products resulting from oxidation of geraniol by a mixture of ozone and oxygen;
dimethylsulfoxide (“DMSO”);
a dye containing a chelated divalent or trivalent metal, wherein the dye comprises a mixture of hematoporphyrin and rose bengal or a mixture of hematoporphyrin and chlorophyllin; and
methylnaphthoquinone.